Congress Materials

Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Azad AA, Iguchi T, Alekseev B, Shore ND, Sugg J, Haas GP, Wozniak M, O'Brien T, Laird AD, Stenzl A, Armstrong AJ June 6, 2022 ASCO 2022 Prostate Cancer

Prevalence of DNA Damage Repair (DDR) Alterations in Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Receiving Enzalutamide (ENZA) or Placebo (PBO) Plus Androgen Deprivation Therapy (ADT): ARCHES Post Hoc Analysis

View Presentation View Abstract Plain Language Summary
Poster
Solomon BJ, Bauer T, Felip E, Liu G, Mazieres J, de Marinis F, Goto Y, Kim D-W, Laktionov K, Blackhall F, Dall'O E, Polli A, Toffalorio F, Mok T June 6, 2022 ASCO 2022 Lung Cancer

Progression-Free Survival With Subsequent Anticancer Therapies From a Phase 3 Trial of Lorlatinib in Treatment-Naive Patients With ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC) 

View Presentation View Abstract Plain Language Summary
Poster
Armstrong AJ, Mottet N, Iguchi T, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Lee H-J, Haas GP, Stenzl A, Azad AA June 6, 2022 ASCO 2022 Prostate Cancer

Radiographic Progression in the Absence of Prostate-Specific Antigen (PSA) Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Post Hoc Analysis of ARCHES

View Presentation View Abstract Plain Language Summary
Poster
Freedland SJ, Klaassen Z, Agarwal N, Sandin R, Leith A, Ribbands A, Clayton E, Butcher J, Gillespie-Akar L, Russell D, Hong A, Ramaswamy K, George DJ June 6, 2022 ASCO 2022 Prostate Cancer

Reasons for Oncologist and Urologist Treatment Choice in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Physician Survey Linked to Patient Chart Reviews in the United States

View Presentation View Abstract Plain Language Summary
Poster
Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen H-C, Lanzalone S, Niyazov A, Fizazi K, for the TALAPRO-3 investigational group June 6, 2022 ASCO 2022 Prostate Cancer

TALAPRO-3: A Phase 3, Double-Blind, Randomized Study of Enzalutamide (ENZA) Plus Talazoparib vs Placebo Plus ENZA in Patients with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

View Presentation View Abstract Plain Language Summary
Poster
Sharifi N, Azad AA, Patel M, Hearn J, Wozniak M, Zohren F, Sugg J, Haas GP, Stenzl A, Armstrong AJ June 6, 2022 ASCO 2022 Prostate Cancer

The Association of Germline HSD3B1 Genotype With Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with or without Enzalutamide (ARCHES)

View Presentation View Abstract Plain Language Summary